Stephen H Friend

List of Publications by Year
in descending order

93 papers	45,457 citations	34105 52 h-index	38395 95 g-index
102 all docs	102 docs citations	102 times ranked	47251 citing authors

#	Article	IF	Citations
1	Stress-related consequences of the coronavirus disease 2019 pandemic on symptoms of Crohnâ€™s disease. European Journal of Gastroenterology and Hepatology, 2021, Publish Ahead of Print, 1511-1516.	1.6	6
2	Disrupting the power balance between doctors and patients in the digital era. The Lancet Digital Health, 2021, 3, e142-e143.	12.3	8
3	An Alternative to the Light Touch Digital Health Remote Study: The Stress and Recovery in Frontline COVID-19 Health Care Workers Study. JMIR Formative Research, 2021, 5, e32165.	1.4	11
4	Evaluation of Combined Artificial Intelligence and Radiologist Assessment to Interpret Screening Mammograms. JAMA Network Open, 2020, 3, e200265.	5.9	236
5	Unlocking stress and forecasting its consequences with digital technology. Npj Digital Medicine, 2019, 2, 75.	10.9	32
6	The Use of Smartphones for Health Research. Academic Medicine, 2017, 92, 157-160.	1.6	138
7	Sulforaphane reduces hepatic glucose production and improves glucose control in patients with type 2 diabetes. Science Translational Medicine, 2017, 9, .	12.4	240
8	The inconvenience of data of convenience: computational research beyond post-mortem analyses. Nature Methods, 2017, 14, 937-938.	19.0	9
9	Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. Lancet Oncology, The, 2017, 18, 132-142.	10.7	124
10	The cancer predisposition revolution. Science, 2016, 352, 1052-1053.	12.6	14
11	Analysis of 589,306 genomes identifies individuals resilient to severe Mendelian childhood diseases. Nature Biotechnology, 2016, 34, 531-538.	17.5	273
12	Crowdsourcing biomedical research: leveraging communities as innovation engines. Nature Reviews Genetics, 2016, 17, 470-486.	16.3	137
13	Challenges in identifying cancer genes by analysis of exome sequencing data. Nature Communications, 2016, 7, 12096.	12.8	34
14	The mPower study, Parkinson disease mobile data collected using ResearchKit. Scientific Data, 2016, 3, 160011.	5.3	439
15	Inferring causal molecular networks: empirical assessment through a community-based effort. Nature Methods, 2016, 13, 310-318.	19.0	209
16	First, design for data sharing. Nature Biotechnology, 2016, 34, 377-379.	17.5	51
17	A Crowdsourcing Approach to Developing and Assessing Prediction Algorithms for AML Prognosis. PLoS Computational Biology, 2016, 12, e1004890.	3.2	28
18	Precompetitive Data Sharing as a Catalyst toÂAddress Unmet Needs in Parkinsonâ€™s Disease 1. Journal of Parkinson's Disease, 2015, 5, 581-594.	2.8	25

#	Article	IF	Citations
19	Combining tumor genome simulation with crowdsourcing to benchmark somatic single-nucleotide-variant detection. Nature Methods, 2015, 12, 623-630.	19.0	282
20	The Prostate Cancer DREAM Challenge: A Community-Wide Effort to Use Open Clinical Trial Data for the Quantitative Prediction of Outcomes in Metastatic Prostate Cancer. Oncologist, 2015, 20, 459-460.	3.7	14
21	App-enabled trial participation: Tectonic shift or tepid rumble?. Science Translational Medicine, 2015, 7, 297ed10.	12.4	12
22	Prediction of human population responses to toxic compounds by a collaborative competition. Nature Biotechnology, 2015, 33, 933-940.	17.5	88
23	Database of Genomic Biomarkers for Cancer Drugs and Clinical Targetability in Solid Tumors. Cancer Discovery, 2015, 5, 118-123.	9.4	109
24	The NIH BD2K center for big data in translational genomics. Journal of the American Medical Informatics Association: JAMIA, 2015, 22, 1143-1147.	4.4	30
25	The consensus molecular subtypes of colorectal cancer. Nature Medicine, 2015, 21, 1350-1356.	30.7	3,596
26	Global optimization of somatic variant identification in cancer genomes with a global community challenge. Nature Genetics, 2014, 46, 318-319.	21.4	42
27	Social Interactomes for Enabling Research Communities. Cancer Discovery, 2014, 4, 1265-1268.	9.4	0
28	Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in Patients. Clinical Cancer Research, 2014, 20, 265-272.	7.0	36
29	Clues from the resilient. Science, 2014, 344, 970-972.	12.6	44
30	Potential of the Synthetic Lethality Principle. Science, 2013, 342, 809-811.	12.6	67
31	Metcalfe's law and the biology information commons. Nature Biotechnology, 2013, 31, 297-303.	17.5	32
32	Genome-wide Methylation Profiles Reveal Quantitative Views of Human Aging Rates. Molecular Cell, 2013, 49, 359-367.	9.7	2,734
33	Improving Breast Cancer Survival Analysis through Competition-Based Multidimensional Modeling. PLoS Computational Biology, 2013, 9, e1003047.	3.2	76
34	Impact of Bioinformatic Procedures in the Development and Translation of High-Throughput Molecular Classifiers in Oncology. Clinical Cancer Research, 2013, 19, 4315-4325.	7.0	32
35	Systematic Analysis of Challenge-Driven Improvements in Molecular Prognostic Models for Breast Cancer. Science Translational Medicine, 2013, 5, 181re1.	12.4	108
36	Crowdsourcing genetic prediction of clinical utility in the Rheumatoid Arthritis Responder Challenge. Nature Genetics, 2013, 45, 468-469.	21.4	24

#	Article	IF	Citations
37	Enabling transparent and collaborative computational analysis of 12 tumor types within The Cancer Genome Atlas. Nature Genetics, 2013, 45, 1121-1126.	21.4	102
38	Developing predictive molecular maps of human disease through community-based modeling. Nature Genetics, 2012, 44, 127-130.	21.4	54
39	Leveraging models of cell regulation and GWAS data in integrative network-based association studies. Nature Genetics, 2012, 44, 841-847.	21.4	252
40	Predictive, personalized, preventive, participatory (P4) cancer medicine. Nature Reviews Clinical Oncology, 2011, 8, 184-187.	27.6	628
41	Predictive Genes in Adjacent Normal Tissue Are Preferentially Altered by sCNV during Tumorigenesis in Liver Cancer and May Rate Limiting. PLoS ONE, 2011, 6, e20090.	2.5	68
42	An accelerated pathway for targeted cancer therapies. Nature Reviews Drug Discovery, 2011, 10, 79-80.	46.4	28
43	The Precompetitive Space: Time to Move the Yardsticks. Science Translational Medicine, 2011, 3, 76cm10.	12.4	24
44	Using Patient-Initiated Study Participation in the Development of Evidence for Personalized Cancer Therapy. Clinical Cancer Research, 2011, 17, 6651-6657.	7.0	7
45	Leveraging Crowdsourcing to Facilitate the Discovery of New Medicines. Science Translational Medicine, 2011, 3, 88mr1.	12.4	42
46	Opening Up to Precompetitive Collaboration. Science Translational Medicine, 2010, 2, 52cm26.	12.4	47
47	A network view of disease and compound screening. Nature Reviews Drug Discovery, 2009, 8, 286-295.	46.4	269
48	Cancer Biomarkers--An Invitation to the Table. Science, 2006, 312, 1165-1168.	12.6	201
49	A simple recipe for drug interaction networks earns its stars. Nature Genetics, 2006, 38, 405-406.	21.4	5
50	Accelerating drug discovery: Open source cancer cell biology?. Cancer Cell, 2006, 10, 349-351.	16.8	6
51	Small Interfering RNA Screens Reveal Enhanced Cisplatin Cytotoxicity in Tumor Cells Having both BRCA Network and TP53 Disruptions. Molecular and Cellular Biology, 2006, 26, 9377-9386.	2.3	176
52	Gene expression changes associated with progression and response in chronic myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 2794-2799.	7.1	525
53	A Cell Proliferation Signature Is a Marker of Extremely Poor Outcome in a Subpopulation of Breast Cancer Patients. Cancer Research, 2005, 65, 4059-4066.	0.9	233
54	Alfred Knudson: The importance of a visionary who enables scientists. Genes Chromosomes and Cancer, 2003, 38, 326-328.	2.8	2

#	Article	IF	Citations
55	Genetics of gene expression surveyed in maize, mouse and man. Nature, 2003, 422, 297-302.	27.8	1,401
56	A Gene-Expression Signature as a Predictor of Survival in Breast Cancer. New England Journal of Medicine, 2002, 347, 1999-2009.	27.0	5,759
57	Gene expression profiling predicts clinical outcome of breast cancer. Nature, 2002, 415, 530-536.	27.8	8,655
58	Toxicogenomics and drug discovery: will new technologies help us produce better drugs?. Nature Reviews Drug Discovery, 2002, 1, 84-88.	46.4	176
59	The Magic of Microarrays. Scientific American, 2002, 286, 44-53.	1.0	46
60	Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer. Nature Biotechnology, 2001, 19, 342-347.	17.5	1,225
61	Microarraysâ€”the 21st century divining rod?. Nature Medicine, 2001, 7, 658-659.	30.7	57
62	Widespread aneuploidy revealed by DNA microarray expression profiling. Nature Genetics, 2000, 25, 333-337.	21.4	454
63	Signaling and Circuitry of Multiple MAPK Pathways Revealed by a Matrix of Global Gene Expression Profiles. Science, 2000, 287, 873-880.	12.6	835
64	Functional Discovery via a Compendium of Expression Profiles. Cell, 2000, 102, 109-126.	28.9	2,412
65	Cheap DNA arraysâ€”it's not all smoke and mirrors. Nature Biotechnology, 1999, 17, 953-953.	17.5	24
66	Strengths and weaknesses in the current applications of expression profiling. Nature Genetics, 1999, 23, 20-20.	21.4	425
67	Functional Characterization of the S. cerevisiae Genome by Gene Deletion and Parallel Analysis. Science, 1999, 285, 901-906.	12.6	3,761
68	Genetic Selection of Peptide Inhibitors of Biological Pathways. Science, 1999, 285, 591-595.	12.6	185
69	Mining the NCI Anticancer Drug Discovery Databases:â€‰Genetic Function Approximation for the QSAR Study of Anticancer Ellipticine Analogues. Journal of Chemical Information and Computer Sciences, 1998, 38, 189-199.	2.8	107
70	Drug target validation and identification of secondary drug target effects using DNA microarrays. Nature Medicine, 1998, 4, 1293-1301.	30.7	635
71	Functional analysis of human MLH1 mutations in Saccharomyces cerevisiae. Nature Genetics, 1998, 19, 384-389.	21.4	136
72	Sibling rivalry, arrested development and chromosomal mayhem. Nature Genetics, 1998, 19, 9-10.	21.4	2

#	Article	IF	Citations
73	Mining the National Cancer Institute Anticancer Drug Discovery Database: Cluster Analysis of Ellipticine Analogs with p53-Inverse and Central Nervous System-Selective Patterns of Activity. Molecular Pharmacology, 1998, 53, 241-251.	2.3	83
74	Emerging Uses for Genomic Information in Drug Discovery. New England Journal of Medicine, 1998, 338, 125-126.	27.0	28
75	Integrating Genetic Approaches into the Discovery of Anticancer Drugs. Science, 1997, 278, 1064-1068.	12.6	699
76	Which guesstimate is the best guesstimate? Predicting chemotherapeutic outcomes. Nature Medicine, 1997, 3, 962-963.	30.7	21
77	Germ-LineBRCA1Mutations in Jewish and Non-Jewish Women with Early-Onset Breast Cancer. New England Journal of Medicine, 1996, 334, 143-149.	27.0	408
78	Pleuropulmonary blastoma: A marker for familial disease. Journal of Pediatrics, 1996, 128, 220-224.	1.8	210
79	Breast cancer susceptibility testing: realities in the postâ€“genomic era. Nature Genetics, 1996, 13, 16-17.	21.4	25
80	Breast cancer information on the web. Nature Genetics, 1995, 11, 238-239.	21.4	33
81	A rapid PCR fidelity assay. Nucleic Acids Research, 1994, 22, 3259-3260.	14.5	111
82	Secondary breast cancer in patients presenting with osteosarcoma: Possible involvement of germline p53 mutations. Medical and Pediatric Oncology, 1994, 23, 354-358.	1.0	16
83	p53: a glimpse at the puppet behind the shadow play. Science, 1994, 265, 334-335.	12.6	153
84	Screening for cancer susceptibility in children. Current Opinion in Pediatrics, 1994, 6, 46-51.	2.0	6
85	Laboratoryâ€“clinical interface. Cancer, 1993, 71, 3219-3221.	4.1	0
86	Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nature Genetics, 1993, 5, 124-129.	21.4	243
87	Germline Mutations of the p53 Tumor-Suppressor Gene in Children and Young Adults with Second Malignant Neoplasms. New England Journal of Medicine, 1992, 326, 1309-1315.	27.0	365
88	Structure and expression of the Xenopus retinoblastoma gene. Developmental Biology, 1992, 153, 141-149.	2.0	47
89	Tempus edax rerum. Cell, 1991, 66, 189-190.	28.9	3
90	Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. Nature, 1988, 334, 124-129.	27.8	1,533

#	Article	IF	Citations
91	Oncogenes and Tumor-Suppressing Genes. New England Journal of Medicine, 1988, 318, 618-622.	27.0	224
92	A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature, 1986, 323, 643-646.	27.8	2,853
93	Discrete charge calculations of potentiometric titrations for globular proteins: Sperm whale myoglobin, hemoglobin alpha chain, cytochrome c. Biochemical and Biophysical Research Communications, 1978, 81, 416-421.	2.1	69